Literature DB >> 33973184

COVID-19 and Cardiovascular Diseases.

Babak Geraiely1, Niloufar Samiei2, Parham Sadeghipour3, Azita H Talasaz4, Seyedeh Hamideh Mortazavi4, Roya Sattarzadeh Badkoubeh5.   

Abstract

We herein seek to expound on up-to-the-minute information regarding cardiovascular disease in the era of coronavirus disease 2019 (COVID-19) by highlighting acute myocardial injury caused by COVID-19 and probing into its pathophysiology, clinical signs, diagnostic tests, and treatment modalities. We aim to share the latest research findings vis-à-vis cardiovascular disease patients with confirmed or suspected COVID-19 on the association between hypertension and this infectious disease along with the relevant recommendations; describe the mechanism of coronary artery disease in such patients together with the necessary measures in the setting of non-ST-segment elevation acute coronary syndrome, ST-segment elevation myocardial infarction, and chronic coronary syndrome; discuss tachy- and bradyarrhythmias in the COVID-19 setting alongside their treatments; elucidate coagulopathies, venous thromboembolism, and its prophylactic measures in the context of this infection; set out the cardiopulmonary resuscitation protocol as well as the pertinent safety concerns during the current pandemic; and, finally, explicate drug-drug interactions between COVID-19 and cardiovascular medication in hypertension, acute coronary syndrome, heart failure, venous thromboembolism, and arrhythmias.

Entities:  

Keywords:  COVID-19; Cardiovascular disease; Outbreak; SARS-CoV-2

Mesh:

Year:  2021        PMID: 33973184     DOI: 10.1007/978-3-030-63761-3_16

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  36 in total

1.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Alida L P Caforio; Sabine Pankuweit; Eloisa Arbustini; Cristina Basso; Juan Gimeno-Blanes; Stephan B Felix; Michael Fu; Tiina Heliö; Stephane Heymans; Roland Jahns; Karin Klingel; Ales Linhart; Bernhard Maisch; William McKenna; Jens Mogensen; Yigal M Pinto; Arsen Ristic; Heinz-Peter Schultheiss; Hubert Seggewiss; Luigi Tavazzi; Gaetano Thiene; Ali Yilmaz; Philippe Charron; Perry M Elliott
Journal:  Eur Heart J       Date:  2013-07-03       Impact factor: 29.983

2.  Non-steroidal Anti-inflammatory Drugs may Worsen the Course of Community-Acquired Pneumonia: A Cohort Study.

Authors:  Damien Basille; Nathalie Plouvier; Charlotte Trouve; Pierre Duhaut; Claire Andrejak; Vincent Jounieaux
Journal:  Lung       Date:  2016-12-22       Impact factor: 2.584

Review 3.  Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.

Authors:  David S Fedson
Journal:  Ann Transl Med       Date:  2016-11

4.  Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.

Authors:  Carlos M Ferrario; Jewell Jessup; Mark C Chappell; David B Averill; K Bridget Brosnihan; E Ann Tallant; Debra I Diz; Patricia E Gallagher
Journal:  Circulation       Date:  2005-05-16       Impact factor: 29.690

Review 5.  Part 7: CPR techniques and devices: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.

Authors:  Diana M Cave; Raul J Gazmuri; Charles W Otto; Vinay M Nadkarni; Adam Cheng; Steven C Brooks; Mohamud Daya; Robert M Sutton; Richard Branson; Mary Fran Hazinski
Journal:  Circulation       Date:  2010-11-02       Impact factor: 29.690

6.  European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS).

Authors:  Giuseppe Boriani; Laurent Fauchier; Luis Aguinaga; James M Beattie; Carina Blomstrom Lundqvist; Ariel Cohen; Gheorghe-Andrei Dan; Simonetta Genovesi; Carsten Israel; Boyoung Joung; Zbigniew Kalarus; Rachel Lampert; Vincenzo L Malavasi; Jacques Mansourati; Lluis Mont; Tatjana Potpara; Andrew Thornton; Gregory Y H Lip
Journal:  Europace       Date:  2019-01-01       Impact factor: 5.214

7.  Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Authors:  Lei Fang; George Karakiulakis; Michael Roth
Journal:  Lancet Respir Med       Date:  2020-03-11       Impact factor: 30.700

8.  Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus.

Authors:  Tariq Alhogbani
Journal:  Ann Saudi Med       Date:  2016 Jan-Feb       Impact factor: 1.526

Review 9.  Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.

Authors:  Elissa Driggin; Mahesh V Madhavan; Behnood Bikdeli; Taylor Chuich; Justin Laracy; Giuseppe Biondi-Zoccai; Tyler S Brown; Caroline Der Nigoghossian; David A Zidar; Jennifer Haythe; Daniel Brodie; Joshua A Beckman; Ajay J Kirtane; Gregg W Stone; Harlan M Krumholz; Sahil A Parikh
Journal:  J Am Coll Cardiol       Date:  2020-03-19       Impact factor: 24.094

Review 10.  Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19).

Authors:  Dave L Dixon; Benjamin W Van Tassell; Alessandra Vecchié; Aldo Bonaventura; Azita H Talasaz; Hessam Kakavand; Fabrizio DʼAscenzo; Antonio Perciaccante; Davide Castagno; Enrico Ammirati; Giuseppe Biondi-Zoccai; Michael P Stevens; Antonio Abbate
Journal:  J Cardiovasc Pharmacol       Date:  2020-05       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.